Validating pig models for Alzheimer's disease

验证阿尔茨海默病猪模型

• 批准号: 10524989
• 负责人: Timothy Alexander Allen
• 金额: $ 44.66万
• 依托单位: UNIVERSITY OF MISSOURI-COLUMBIA
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-08-01 至 2024-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10524989
• 关键词: Address; Affect; Age; Aging; Alzheimer' s Disease; Alzheimer' s disease model; Amyloid beta-Protein; Animal Experimentation; Animal Model; Animals; Area; Basic Science; Behavior; Behavioral; Biochemical; Biological Process; Brain; Brain region; Cardiovascular system; Cause of Death; Clinical; Cognition; Cognitive; Collection; Communities; Data; Data Set; Dementia; Development; Disease; Dose; Early Onset Alzheimer Disease; Endocrine; Engineering; Evaluation; Family suidae; Florida; Foundations; Functional disorder; Genetic Engineering; Genome; Goals; Gold; Healthcare; Histologic; Human; Immune; Immunohistochemistry; Interdisciplinary Study; International; Knock-out; Late Onset Alzheimer Disease; Longevity; Lung; Measures; Memory; Memory Loss; Metabolic; Miniature Swine; Missouri; Modeling; Molecular; Mus; Neurocognitive; Neurodegenerative Disorders; Neurosciences; Neurosciences Research; Pathologic; Pathology; Persons; Pharmaceutical Preparations; Phenocopy; Phenotype; Physiology; Population; Preclinical Drug Development; Quality of life; Research; Resources; Response to stimulus physiology; Rodent; Rodent Model; Schedule; Science; Senile Plaques; Stains; Standardization; Structure; Symptoms; System; Tauopathies; Testing; Therapeutic; Therapeutic Intervention; Translational Research; Traumatic Brain Injury; Universities; Validation; Work; age related; aged; base; brain tissue; clinically relevant; cognitive task; cost estimate; drug discovery; early onset; effective therapy; familial Alzheimer disease; improved; interdisciplinary collaboration; member; model development; neurocognitive test; neurophysiology; neurotoxicity; neurovascular; novel; pig genome; porcine model; pre-clinical; presenilin-1; response; therapeutic development; touchscreen; transcriptome sequencing; translational goal; translational model; translational progress

Project Summary/Abstract The broad goal of this proposal is to characterize and establish pig models of Alzheimer’s disease (AD). The specific purpose is to collect novel validation data in three pig AD models including APP, PSEN1, and 5xFAD pigs lacking their endogenous APP and PSEN1. Using our expertise, the pig models will be validated to reflect cellular, molecular, and behavior aspect of the disease. AD is the leading cause of dementia and affects estimated 6.2 million people in the U.S. population, yet there remains need to develop effective treatments. Rodent models of AD have provided critical information regarding the underlying pathophysiology of this disorder. However, these models cannot capture many aspects of the human physiology, and clinical drug doses cannot be examined in smaller animals. Large animal models of AD are thus needed to facilitate our understanding of this disorder and accelerate drug discovery efforts. Pigs are readily available and are considered to be an excellent biomedical model due to numerous similarities to humans, including cardiovascular, pulmonary, immune, endocrine and metabolic systems. Additionally, in comparison to rodent models, pigs are larger, have longer lifespans and a more similar brain structure compared to humans. Importantly, pigs can perform complicated cognitive tasks making them an ideal large animal model of AD, which is defined by a substantial decline in memory capabilities. Currently, there are no large animal models that accurately reflect the symptoms of Alzheimer’s disease in the U.S. To address this significant gap in the field, we will validate the first pig models of AD available in the U.S. Diversifying animal models representing human AD will be invaluable for developing therapeutics to improve the longevity and quality of life in AD. To achieve this goal, we have assembled an interdisciplinary research team including members of the National Swine Resource and Research Center (NSRRC) at the University of Missouri and the Porcine Neuroscience Facility (PNF) at Florida International University that has all the necessary expertise to develop and characterize these pig AD models. In Aim 1 we will characterize the genome and biological processes of our APP, PSEN1 and 5xFAD pig AD models to help establish them as a novel resource to biomedical community. In Aim 2 we will further validate the AD pig models for their use in AD research by performing brain region-specific histological evaluations and neurocognitive assessments. Thus, we expect to confirm phenocopies of AD in these pig models at molecular, biochemical, and cognitive levels. Collectively, this proposal will result in collection of critical data that is needed to assess the validity of these new pig models for AD, which can serve as a novel resource to the biomedical community and help advance our understanding and potential treatments of this major neurodegenerative disorder.

项目总结/摘要 该提案的主要目标是表征和建立阿尔茨海默病（AD）的猪模型。的 具体目的是在三种猪AD模型（包括APP、PSEN 1和5xFAD）中收集新的验证数据 缺乏内源性APP和PSEN 1的猪。利用我们的专业知识，将对猪模型进行验证，以反映 细胞、分子和行为方面的疾病。AD是痴呆症的主要原因， 据估计，美国人口中有620万人，但仍然需要开发有效的治疗方法。 AD的啮齿动物模型提供了关于这种疾病的潜在病理生理学的关键信息。 disorder.然而，这些模型不能捕捉人体生理学和临床药物剂量的许多方面 不能在较小的动物中检测。因此，需要AD的大型动物模型来促进我们的研究。 了解这种疾病并加速药物发现工作。猪很容易获得，并且 被认为是一个很好的生物医学模型，因为它与人类有许多相似之处，包括 心血管、肺、免疫、内分泌和代谢系统。此外，与啮齿动物相比， 猪的体型更大，寿命更长，大脑结构与人类更相似。 重要的是，猪可以执行复杂的认知任务，使其成为理想的AD大型动物模型， 是由记忆能力的大幅下降所定义的。目前，还没有大型动物模型， 准确地反映了美国阿尔茨海默病的症状。 在这一领域，我们将验证美国第一个AD猪模型。 人AD对于开发治疗剂以改善AD的寿命和生活质量将是非常宝贵的。到 为了实现这一目标，我们组建了一个跨学科的研究团队，包括国家科学院的成员。 密苏里州大学猪资源和研究中心（NSRRC）和猪神经科学 设施（PNF）在佛罗里达国际大学，具有所有必要的专业知识，以开发和表征 这些猪广告模特在目标1中，我们将描述我们的APP，PSEN 1的基因组和生物学过程 和5xFAD猪AD模型，以帮助建立它们作为生物医学界的新资源。在目标2中， 通过进行脑区域特异性组织学检查，进一步验证AD猪模型用于AD研究 评估和神经认知评估。因此，我们希望在这些猪模型中证实AD的表型 在分子生物化学和认知水平上。总的来说，这一提议将导致收集关键数据 需要评估这些新的猪模型对AD的有效性，这可以作为一种新的资源， 生物医学界和帮助推进我们的理解和潜在的治疗这一重大 神经退行性疾病